The holder of an original marketing authorisation issued under the procedure referred to in Directive 65/65 may rely on the provisions of that directive in proceedings before a national court in order to challenge the validity of an authorisation issued by the competent national authority on the basis of Directive 65/65 to one of its competitors for a proprietary medicinal product bearing the same name.
The same applies where the authorisation, although issued under another procedure laid down at national level, should have been issued on the basis of the directive.
I.e. administrative decisions can be challenged by virtue of the fact that, had they used the proper procedure under an unimplemented directive, they would have been taken differently.
Ask questions 🙋 Get answers 📔 It's simple 👁️👄👁️
Our AI is educated by the highest scoring students across all subjects and schools. Join hundreds of your peers today.
Get StartedThese product samples contain the same concepts we cover in this case.